To administer regulated electrical stimulation to the sacral nerves, a tiny device known as a neurostimulator is implanted beneath the skin during sacral nerve stimulation therapy. The control of bowel and bladder function depends on these nerves. With electrodes close to the sacral nerves, the neurostimulator can modify nerve activity and alleviate symptoms of disorders like urine and fecal incontinence.
Increased incidences of urological disorders like chronic anal fissure, urinary & fecal incontinence, and overactive bladder syndrome, an upsurge in the population's average age, technological advancements, and increased public awareness of the market are the main factors propelling the market's growth. For instance, research from the American Urological Association states that one-third of men and women in the US experience urine incontinence. Thirty-three million people have an overactive bladder, which can cause urgency sensations. Because sacral nerve stimulation is a successful treatment for urological incontinence, the prevalence of this ailment is increasing, boosting the need for it.
Increased prevalence of overactive bladder (OAB) and urge incontinence, increased knowledge of available treatments, and rising use of technologically advanced medical devices, including implantable sacral nerve stimulation (SNS) devices, are all expected to contribute to the market growth in North America. As a result, the high rate of diabetes in the American population is also accompanied by a significant rate of urinary tract infections (UTIs), which raises the demand for surgical operations and fuels the market's expansion. As a result, the rising incidence of urine incontinence in the region will probably be one of the key elements influencing the market under study during the coming years.
The US market dominated the North America Sacral Nerve Stimulation Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $159.9 Million by 2030. The Canada market is poised to grow at a CAGR of 6.8% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 5.9% during (2023-2030).
Based on Application, the market is segmented into Urinary & Fecal Incontinence, Chronic Anal Fissure, and Others. Based on Product, the market is segmented into Devices, and Accessories. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Axonics, Inc., Beijing PINS Medical Co., Ltd., PZMed, Laborie Medical Technologies, Synapse BioMedical, Inc., Johnson and Johnson, LivaNova PLC, Boston Scientific Corporation, and Saluda Medical Pty Ltd.
Scope of the Study
By Application
- Urinary & Fecal Incontinence
- Chronic Anal Fissure
- Others
By Product
- Devices
- Accessories
By End-user
- Hospitals
- Specialty Clinics
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- PZMed
- Laborie Medical Technologies
- Synapse BioMedical, Inc.
- Johnson and Johnson
- LivaNova PLC
- Boston Scientific Corporation
- Saluda Medical Pty Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Medtronic PLC
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- PZMed
- Laborie Medical Technologies
- Synapse BioMedical, Inc.
- Johnson and Johnson
- LivaNova PLC
- Boston Scientific Corporation
- Saluda Medical Pty Ltd.
Methodology
LOADING...